enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Enfortumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Enfortumab_vedotin

   Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]

3. Seattle Genetics Up on Positive Data From Bladder Cancer Study

   www.aol.com/news/seattle-genetics-positive-data...

   Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.

4. Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

   www.aol.com/news/seattle-genetics-enfortumab...

   The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

5. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   reduction of side effects of cardiac surgery: Pidilizumab [40] mab: humanized: PD-1: cancer and infectious diseases Pinatuzumab vedotin [40] mab: humanized: CD22: cancer Pintumomab: mab: mouse: adenocarcinoma antigen: adenocarcinoma (imaging) Placulumab [15] mab: human: TNF: pain and inflammatory diseases Pozelimab [35] Veopoz: mab: human: C5 ...

6. Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA ... - AOL

   www.aol.com/news/seagens-sgen-maa-enfortumab...

   The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.

7. Bladder cancer - Wikipedia

   en.wikipedia.org/wiki/Bladder_cancer

   Bladder cancer is much more common in men than women; around 1.1% of men and 0.27% of women develop bladder cancer. [2] This makes bladder cancer the sixth most common cancer in men, and the seventeenth in women. [59] When women are diagnosed with bladder cancer, they tend to have more advanced disease and consequently a poorer prognosis. [59]